Related Experiment Video
Updated: Jun 29, 2026
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
[Leukemic cell apoptosis induced by anti-human DR5 monoclonal antibody mDRA-6]
Shu-lian Li1, Yuan-fang Ma, Guang-chao Liu
1Institute of Immunology, Laboratory of Cellular and Molecular Immunology, Henan University, Kaifeng 475004, China. lshl92627@henu.edu.cn
Aim:
To investigate the apoptotic effect of anti-human DR5 (death receptor 5 of TRAIL) monoclonal antibody mDRA-6 on leukemic cells.
Methods:
The morphological changes of leukemic cells were observed by fluorescence microscope. The cytotoxic and apoptotic effects of mDRA-6 on Jurkat, HL-60 and K562 cells were detected by MTT analysis and flow cytometry with Annexin V-FITC/PI staining.
Results:
Chromatin condensation, budding and apoptotic bodies were observed in Jurkat and HL-60 cells treated by mDRA-6. Death and apoptosis of leukemic cells treated by mDRA-6 were increased, but the effect of mDRA-6 on K562 cells was not obvious.
Conclusion:
Apoptosis of leukemic cells can be induced by anti-human DR5 monoclonal antibody mDRA-6. Different leukemic cell lines are of different sensitivity to mDRA-6.
Insights
The anti-human DR5 monoclonal antibody mDRA-6 induces apoptosis in certain leukemia cells. Sensitivity varies among different leukemic cell lines, with K562 cells showing less response.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Context:
- Leukemia remains a significant health concern, necessitating novel therapeutic strategies.
- Targeting death receptors like DR5 offers a promising avenue for cancer treatment.
- Monoclonal antibodies are key biologics in modern cancer therapy.
Purpose:
- To evaluate the efficacy of mDRA-6, a monoclonal antibody targeting human DR5 (death receptor 5).
- To investigate the induction of apoptosis and cytotoxicity in various leukemia cell lines by mDRA-6.
Summary:
- Morphological analysis revealed chromatin condensation and apoptotic bodies in Jurkat and HL-60 cells post-mDRA-6 treatment.
- MTT assays and Annexin V-FITC/PI staining confirmed increased leukemic cell death and apoptosis.
- K562 cells exhibited a less pronounced response to mDRA-6 compared to Jurkat and HL-60 cells.
Impact:
- Demonstrates the potential of mDRA-6 as an apoptosis-inducing agent for specific leukemia types.
- Highlights the differential sensitivity of leukemia cell lines to DR5-targeted therapy.
- Provides a basis for further research into mDRA-6 and DR5-targeted treatments in hematologic malignancies.
